Log In
BCIQ
Print this Print this
 

esketamine

  Manage Alerts
Collapse Summary General Information
Company Johnson & Johnson
DescriptionIntranasal NMDA receptor antagonist
Molecular Target NMDA receptor
Mechanism of ActionNMDA receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase III
Standard IndicationDepression
Indication DetailsTreat major depression; Treat major depressive disorder (MDD) in patients assessed to be at imminent risk for suicide; Treat treament-resistant depression
Regulatory Designation U.S. - Breakthrough Therapy (Treat treament-resistant depression);
U.S. - Breakthrough Therapy (Treat major depressive disorder (MDD) in patients assessed to be at imminent risk for suicide)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today